|

Vismodegib Clinical Trials

10 actively recruiting trials across 4 locations

Also known as: ERIVEDGE, Erivedge, GDC 0449, GDC-0449, GDC0449 +1 more

Pipeline

Phase 1: 1Phase 2: 8

Top Sponsors

  • University Hospital, Lille1
  • Ulrik Lassen1
  • The Netherlands Cancer Institute1
  • Stamford Pharmaceuticals, Inc.1
  • Ronald Buckanovich1

Indications

  • Cancer10
  • Basal Cell Carcinoma3
  • Neoplasia2
  • Tumors2
  • NF2 Gene Mutation1

Other6 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Phase 2
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Phase 2
Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Birmingham, Alabama1 trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

University of Alabama at Birmingham Cancer Center

Phase 2

Phoenix, Arizona1 trial

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Research Site

Phase 2

Columbus, Ohio1 trial

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1

Pittsburgh, Pennsylvania1 trial

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

UPMC Hillman Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.